Cargando…
Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589903/ https://www.ncbi.nlm.nih.gov/pubmed/34478126 http://dx.doi.org/10.1007/s40123-021-00385-8 |
_version_ | 1784598832181411840 |
---|---|
author | Cockerham, Kimberly P. Padnick-Silver, Lissa Stuertz, Noel Francis-Sedlak, Megan Holt, Robert J. |
author_facet | Cockerham, Kimberly P. Padnick-Silver, Lissa Stuertz, Noel Francis-Sedlak, Megan Holt, Robert J. |
author_sort | Cockerham, Kimberly P. |
collection | PubMed |
description | INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limited data on chronic TED patient-reported outcomes. This study examined chronic US TED patient-reported symptoms and quality of life (QOL). METHODS: Existing data from an online survey regarding chronic TED signs/symptoms and patient QOL were retrospectively examined. The Graves’ Ophthalmopathy QOL instrument (GO-QOL; 0–100, 100 = highest QOL) evaluated overall, appearance, and vision-related QOL. Influencing factors were examined by stratifying patients into low (overall QOL ≤ 50), moderate (> 50 and < 75), and high (≥ 75) QOL categories. RESULTS: One hundred patients (47 women, 81 Caucasian, 45.2 ± 7.6 years) were included. The duration of inactive TED was 3.0 ± 4.6 years and total duration of TED was 5.8 ± 5.9 years. Patients reported an average of 20 doctor visits/year and high prevalence of anxiety (34%) and depression (28%). Prior TED treatments for the polled population included systemic corticosteroids during active TED (25%), orbital radiation (5%), and surgery (25%). The overall GO-QOL score was 60.5 ± 21.8 (vision-related: 58.6 ± 24.0, appearance-related: 62.3 ± 25.1). Patients with low QOL more frequently reported hypothyroidism, anxiety, and a larger number of chronic TED signs/symptoms (average: 4.2). Compared to high QOL patients, low QOL patients had more pain (39% vs. 13%), blurry vision (30% vs. 17%), and diplopia (27% vs. 3%, all p ≤ 0.025). Additionally, the low QOL group more often had TED-specific surgical history (45% vs. 10%, p = 0.002), more often reported disability/unemployment (21% vs. 3%, p = 0.055), and had a higher number of doctor visits (40 vs. 5 visits/person/year, p < 0.001). CONCLUSION: TED severely impacts patient QOL, despite becoming stable and chronic. Patients reported vision and appearance impairment and psychosocial impact long after acute TED had subsided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00385-8. |
format | Online Article Text |
id | pubmed-8589903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-85899032021-11-23 Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States Cockerham, Kimberly P. Padnick-Silver, Lissa Stuertz, Noel Francis-Sedlak, Megan Holt, Robert J. Ophthalmol Ther Original Research INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limited data on chronic TED patient-reported outcomes. This study examined chronic US TED patient-reported symptoms and quality of life (QOL). METHODS: Existing data from an online survey regarding chronic TED signs/symptoms and patient QOL were retrospectively examined. The Graves’ Ophthalmopathy QOL instrument (GO-QOL; 0–100, 100 = highest QOL) evaluated overall, appearance, and vision-related QOL. Influencing factors were examined by stratifying patients into low (overall QOL ≤ 50), moderate (> 50 and < 75), and high (≥ 75) QOL categories. RESULTS: One hundred patients (47 women, 81 Caucasian, 45.2 ± 7.6 years) were included. The duration of inactive TED was 3.0 ± 4.6 years and total duration of TED was 5.8 ± 5.9 years. Patients reported an average of 20 doctor visits/year and high prevalence of anxiety (34%) and depression (28%). Prior TED treatments for the polled population included systemic corticosteroids during active TED (25%), orbital radiation (5%), and surgery (25%). The overall GO-QOL score was 60.5 ± 21.8 (vision-related: 58.6 ± 24.0, appearance-related: 62.3 ± 25.1). Patients with low QOL more frequently reported hypothyroidism, anxiety, and a larger number of chronic TED signs/symptoms (average: 4.2). Compared to high QOL patients, low QOL patients had more pain (39% vs. 13%), blurry vision (30% vs. 17%), and diplopia (27% vs. 3%, all p ≤ 0.025). Additionally, the low QOL group more often had TED-specific surgical history (45% vs. 10%, p = 0.002), more often reported disability/unemployment (21% vs. 3%, p = 0.055), and had a higher number of doctor visits (40 vs. 5 visits/person/year, p < 0.001). CONCLUSION: TED severely impacts patient QOL, despite becoming stable and chronic. Patients reported vision and appearance impairment and psychosocial impact long after acute TED had subsided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00385-8. Springer Healthcare 2021-09-03 2021-12 /pmc/articles/PMC8589903/ /pubmed/34478126 http://dx.doi.org/10.1007/s40123-021-00385-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Cockerham, Kimberly P. Padnick-Silver, Lissa Stuertz, Noel Francis-Sedlak, Megan Holt, Robert J. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title | Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title_full | Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title_fullStr | Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title_full_unstemmed | Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title_short | Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States |
title_sort | quality of life in patients with chronic thyroid eye disease in the united states |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589903/ https://www.ncbi.nlm.nih.gov/pubmed/34478126 http://dx.doi.org/10.1007/s40123-021-00385-8 |
work_keys_str_mv | AT cockerhamkimberlyp qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates AT padnicksilverlissa qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates AT stuertznoel qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates AT francissedlakmegan qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates AT holtrobertj qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates |